Assembly Biosciences (ASMB) Operating Margin (2017 - 2026)
Assembly Biosciences' (ASMB) quarterly Operating Margin came in at 138.44% in Q1 2026, down 3290.0% year-on-year from 4.34% in Q1 2025, and down 396.95% quarter-over-quarter from 46.62% in Q4 2025.
Assembly Biosciences (ASMB) Operating Margin (2017 - 2026) Analysis & Trends
Assembly Biosciences' Operating Margin history runs 9 years deep, the most recent figure standing at 138.44% for Q1 2026.
- On a quarterly basis, Operating Margin fell 3290.0% year-over-year to 138.44% in Q1 2026; TTM through Mar 2026 was 19.05%, a 11975.0% increase from a year earlier, with the FY2025 full-year figure at 16.76%, up 14250.0% from the prior year.
- Operating Margin fell to 138.44% in Q1 2026 per ASMB's latest filing, from 46.62% in the prior quarter.
- Across five years, Operating Margin topped out at 46.62% in Q4 2025 and bottomed at 185.46% in Q1 2024.
- The 4-year median for Operating Margin is 140.72% (2026), against an average of 123.4%.
- Across the five-year window, Operating Margin jumped 20337 bps in 2025 and slumped 3290 bps in 2026, its largest moves.
- Year by year, Operating Margin stood at 175.22% in 2023, then rose by 11 bps to 156.75% in 2024, then jumped by 130 bps to 46.62% in 2025, then slumped by 397 bps to 138.44% in 2026.
- Per Business Quant, the three latest ASMB Operating Margin figures stand at 138.44% (Q1 2026), 46.62% (Q4 2025), and 100.87% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Assembly Biosciences | 431.63 Mn | 205.03 Mn | - | -138.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -138.44% |
| Dec 31, 2025 | 46.62% |
| Sep 30, 2025 | -100.87% |
| Jun 30, 2025 | -115.24% |
| Mar 31, 2025 | -105.54% |
| Dec 31, 2024 | -156.75% |
| Sep 30, 2024 | -160.06% |
| Jun 30, 2024 | -143.01% |
| Mar 31, 2024 | -185.46% |
| Dec 31, 2023 | -175.22% |
| Sep 30, 2021 | -301.81% |
| Dec 31, 2020 | -3,822.76% |
| Sep 30, 2020 | -11.61% |
| Jun 30, 2020 | 16.71% |
| Mar 31, 2020 | -678.61% |
| Dec 31, 2019 | -601.72% |
| Sep 30, 2019 | -614.35% |
| Jun 30, 2019 | -639.61% |
| Mar 31, 2019 | -729.37% |
| Dec 31, 2018 | -704.74% |